EnsoData simplifies the process of reading and analyzing the human body to help quickly and accurately diagnose conditions, starting with sleep. Using artificial intelligence, its technology analyzes billions of data points collected from sensors placed throughout the entire human body to help clinicians quickly and consistently make diagnoses. Heartbeats on an EKG, eye movements through an EOG, and brain waves through an EEG all output as waveform data. The company is based in Madison, Wisconsin, and was founded in 2015.

Vectorious Medical Technologies is developing a cardiac monitoring system for congestive heart failure patients. Vectorious technology helps physicians to help patients help themselves. Via a simple, minimally-invasive implanted device, easy-to-access data and user-friendly external home-unit; the Vectorious system increases CHF patient quality of life and reduces readmission rates.

Cardiac Insight is focused on developing advanced body-worn sensing and computing technologies for diagnostic testing in cardiology, respiratory, and other complex disease states. The company seeks to do more than incrementally improve diagnostics and treatment, but rather to invent complete solutions to unmet clinical needs.On March 16th, 2022, Cardiac Insight was acquired by DreamTech. The terms of the transaction were not disclosed.

V-Wave has developed a miniature valve that is implanted by catheterization into the left ventricle. This reduces the pressure on the muscle by controlling the blood flow between the heart chambers in patients who are frequently hospitalized with heart attacks. The valve is intended to reduce hospitalizations and improve patients' quality of life.

Sensome develops micro-sensor technology for smart medical devices. Sensome's sensing technology can be integrated with any medical device to reliably identify biological tissues in contact with the device. The technology combines micrometric impedance sensors that communicate wirelessly outside the body and machine learning algorithms for accurate and predictive real-time analysis.

Implandata Ophthalmic Products offers the EYEMATE system to empower people to take control of glaucoma – anytime and anywhere. EYEMATE is an AI-powered, cloud-based, data-centric platform for 24/7/365 monitoring and predictive modeling of disease progression. EYEMATE's data analytics combine IOP with other vital parameters to enable personalized therapies. For people with glaucoma, this means improved quality of life and peace of mind. For eye doctors, this means improved patient care at a significantly lower cost.